



Vaccine Fact Sheet

Zoster/Shingles (HZV)

Protects Against Herpes Zoster (shingles)

Brand Name and Manufacturer Shingrix
GSK

Routine Schedule 2 dose series, spaced 2 to 6 months apart

Approved for use in Adults 18 and older (see FDA package insert for age groups/indications)
<https://www.fda.gov/media/108597/download>

Recommended for use in All adults 50 years of age and older
Adults 19 years and older with immunocompromising conditions

Administration Intramuscular (IM) injection

Packaging A package of 1 dose contains one vial of lyophilized antigen and one vial of liquid adjuvant component
A package of 10 doses contains 10 vials of lyophilized antigen and 10 vials of liquid adjuvant component

Storage Refrigerate between 36° and 46°
(2° to 8° C)
PROTECT VACCINE FROM LIGHT.
DO NOT FREEZE. Discard if frozen

Full ACIP Recommendations <https://www.cdc.gov/mmwr/volumes/67/wr/mm6703a5.htm>
2022 MMWR: <https://www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm>

VFC Letter Not applicable: RZV is not a pediatric vaccine

Billing Codes CPT Code for vaccine: 90750
CPT code for administration: 90471 or 90742
ICD-10-CM code: Z23
Administration Modifier for MediCare: GY

Comments

- Approved by FDA in 2017
- Patients who have had shingles or previously received Zostavax are also recommended to be vaccinated with Shingrix
- If administered SC, it is not necessary to repeat dose